Cell plasticity represents the ability of cells to be reprogrammed and to change their fate and
identity, enabling homeostasis restoration and tissue regeneration following damage. Cell …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Transcriptional heterogeneity among malignant cells of a tumor has been studied in
individual cancer types and shown to be organized into cancer cell states; however, it …

Single-cell atlases promise to provide a 'missing link'between genes, diseases and
therapies. By identifying the specific cell types, states, programs and contexts where disease …

In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Triggering receptors expressed on myeloid cells (TREMs) encompass a family of cell-
surface receptors chiefly expressed by granulocytes, monocytes and tissue macrophages …

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …

Fibroblasts are non-haematopoietic structural cells that define the architecture of organs,
support the homeostasis of tissue-resident cells and have key roles in fibrosis, cancer …

Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor
microenvironment together determine disease progression, as well as response to or …

Tumor evolution is driven by the progressive acquisition of genetic and epigenetic
alterations that enable uncontrolled growth and expansion to neighboring and distal tissues …